Loading…
Loading…
Could you comment on when we should start seeing results from your Skyrizi and Rinvoq combination trials
how do you kind of expect to maintain this leadership position when other manufacturers launch biosimilars in the second half of the year?
Could we see PK comparability versus randomized Phase III trials to be feasible? And how could these dynamics possibly modulate your long-term guidance of greater than $4 billion in sales by 2030?
Are you thinking a 50-50 split in, let's say, the atopic dermatitis market? Or how are you kind of thinking about that shaking out?
what is Amgen's stance on looking overseas for clinical-stage assets? And I guess more broadly, what is your appetite for M&A now post the Horizon acquisition?
How should we think about the potential of the 340B channel mix on HIV pricing for '25
On Milvexian, can you talk a little bit about confidence in this asset? What do you think you'll need to show to be competitive
Why now, why the orthopedic separation? It's been a hallmark of Johnson & Johnson to be a good steward
can you walk us through J&J's launch strategy? Are there sales force training, supply chain, patient access
For CAPLYTA, how should we be thinking about the cadence of sales growth to the forecasted sales of $5 billion?
how should we think about the potential for lower doses of oloralintide and lower dose combos of tirzepatide
Can you walk us through the importance of the upcoming ATTAIN-MAINTAIN trial to orforglipron's commercial opportunity
Does that suggest that you think there was an underlying driver of these unusually elevated dropout rates across all arms?
Can you update us as to where we are from that events point of view and remind us of what a successful trial looks like?
how does Lilly envision this relationship evolving? And a follow-up, can you help frame the opportunity associated with Zepbound vials?
how should we model the IP runway for KEYTRUDA? And how should we think about the timing
What's the bar to deem the trial a success? And I guess given the competitive nature of this indication
what combinations and indications could we expect? And when could we receive updates
How important do you see this wording update to an impact to US sales